218 related articles for article (PubMed ID: 38191613)
1. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.
Verschoor YL; van de Haar J; van den Berg JG; van Sandick JW; Kodach LL; van Dieren JM; Balduzzi S; Grootscholten C; IJsselsteijn ME; Veenhof AAFA; Hartemink KJ; Vollebergh MA; Jurdi A; Sharma S; Spickard E; Owers EC; Bartels-Rutten A; den Hartog P; de Miranda NFCC; van Leerdam ME; Haanen JBAG; Schumacher TN; Voest EE; Chalabi M
Nat Med; 2024 Feb; 30(2):519-530. PubMed ID: 38191613
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study.
Li N; Li Z; Fu Q; Zhang B; Zhang J; Wan XB; Lu CM; Wang JB; Deng WY; Ma YJ; Bie LY; Wang MY; Li J; Xia QX; Wei C; Luo SX
Int J Surg; 2024 Apr; 110(4):2071-2084. PubMed ID: 38320099
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.
Jiang H; Yu X; Li N; Kong M; Ma Z; Zhou D; Wang W; Wang H; Wang H; He K; Li Z; Lu Y; Zhang J; Zhao K; Zhang Y; Xu N; Li Z; Liu Y; Wang Y; Wang Y; Teng L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296556
[TBL] [Abstract][Full Text] [Related]
4. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma.
Manji GA; Lee S; Del Portillo A; May M; Ana SS; Alouani E; Sender N; Negri T; Gautier K; Ge L; Fan W; Xie M; Sethi A; Schrope B; Tan AC; Park H; Oberstein PE; Shah MA; Raufi AG
JAMA Oncol; 2023 Dec; 9(12):1702-1707. PubMed ID: 37856106
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma.
Sun W; Veeramachaneni N; Al-Rajabi R; Madan R; Kasi A; Al-Kasspooles M; Baranda J; Saeed A; Phadnis MA; Godwin AK; Olyaee M; Streeter N; Nagji A; Dai J; Williamson S
Cancer Med; 2023 Aug; 12(15):16098-16107. PubMed ID: 37326317
[TBL] [Abstract][Full Text] [Related]
7. Perioperative treatment and biomarker analysis of LP002, an anti-PD-L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer.
Tang JL; Zhang B; Xu JP; Qi L; Xin D; Wang L; Wang BZ; Tian YT; Li Y; Huang J
Cancer Med; 2023 Mar; 12(5):5639-5648. PubMed ID: 36341590
[TBL] [Abstract][Full Text] [Related]
8. Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
Xu J; Bai Y; Xu N; Li E; Wang B; Wang J; Li X; Wang X; Yuan X
Clin Cancer Res; 2020 Sep; 26(17):4542-4550. PubMed ID: 32561664
[TBL] [Abstract][Full Text] [Related]
9. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
Jiang H; Zheng Y; Qian J; Mao C; Xu X; Li N; Xiao C; Wang H; Teng L; Zhou H; Wang S; Zhu D; Peng B; Shen L; Xu N
BMC Cancer; 2020 Aug; 20(1):760. PubMed ID: 32795349
[TBL] [Abstract][Full Text] [Related]
11. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
Lorenzen S; Biederstädt A; Ronellenfitsch U; Reißfelder C; Mönig S; Wenz F; Pauligk C; Walker M; Al-Batran SE; Haller B; Hofheinz RD
BMC Cancer; 2020 Sep; 20(1):886. PubMed ID: 32933498
[TBL] [Abstract][Full Text] [Related]
12. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.
Xu J; Jiang H; Pan Y; Gu K; Cang S; Han L; Shu Y; Li J; Zhao J; Pan H; Luo S; Qin Y; Guo Q; Bai Y; Ling Y; Yang J; Yan Z; Yang L; Tang Y; He Y; Zhang L; Liang X; Niu Z; Zhang J; Mao Y; Guo Y; Peng B; Li Z; Liu Y; Wang Y; Zhou H;
JAMA; 2023 Dec; 330(21):2064-2074. PubMed ID: 38051328
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
Bang YJ; Kang YK; Catenacci DV; Muro K; Fuchs CS; Geva R; Hara H; Golan T; Garrido M; Jalal SI; Borg C; Doi T; Yoon HH; Savage MJ; Wang J; Dalal RP; Shah S; Wainberg ZA; Chung HC
Gastric Cancer; 2019 Jul; 22(4):828-837. PubMed ID: 30911859
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Kawazoe A; Yamaguchi K; Yasui H; Negoro Y; Azuma M; Amagai K; Hara H; Baba H; Tsuda M; Hosaka H; Kawakami H; Oshima T; Omuro Y; Machida N; Esaki T; Yoshida K; Nishina T; Komatsu Y; Han SR; Shiratori S; Shitara K
Eur J Cancer; 2020 Apr; 129():97-106. PubMed ID: 32145474
[TBL] [Abstract][Full Text] [Related]
15. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Janjigian YY; Maron SB; Chatila WK; Millang B; Chavan SS; Alterman C; Chou JF; Segal MF; Simmons MZ; Momtaz P; Shcherba M; Ku GY; Zervoudakis A; Won ES; Kelsen DP; Ilson DH; Nagy RJ; Lanman RB; Ptashkin RN; Donoghue MTA; Capanu M; Taylor BS; Solit DB; Schultz N; Hechtman JF
Lancet Oncol; 2020 Jun; 21(6):821-831. PubMed ID: 32437664
[TBL] [Abstract][Full Text] [Related]
16. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
André T; Tougeron D; Piessen G; de la Fouchardière C; Louvet C; Adenis A; Jary M; Tournigand C; Aparicio T; Desrame J; Lièvre A; Garcia-Larnicol ML; Pudlarz T; Cohen R; Memmi S; Vernerey D; Henriques J; Lefevre JH; Svrcek M
J Clin Oncol; 2023 Jan; 41(2):255-265. PubMed ID: 35969830
[TBL] [Abstract][Full Text] [Related]
18. Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Peng Z; Wei J; Wang F; Ying J; Deng Y; Gu K; Cheng Y; Yuan X; Xiao J; Tai Y; Wang L; Zou J; Zhang Y; Shen L
Clin Cancer Res; 2021 Jun; 27(11):3069-3078. PubMed ID: 33766817
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction.
Zhu M; Chen C; Foster NR; Hartley C; Mounajjed T; Salomao MA; Fruth BF; Beamer SE; Kim Y; Harrington SM; Pitot HC; Sanhueza CT; Feng Y; Herrmann J; McWilliams RR; Lucien F; Huang BQ; Ma WW; Bekaii-Saab TS; Dong H; Wigle D; Ahn DH; Hallemeier CL; Blackmon S; Yoon HH
Clin Cancer Res; 2022 Jul; 28(14):3021-3031. PubMed ID: 35552651
[TBL] [Abstract][Full Text] [Related]
20. Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.
Lorenzen S; Götze TO; Thuss-Patience P; Biebl M; Homann N; Schenk M; Lindig U; Heuer V; Kretzschmar A; Goekkurt E; Haag GM; Riera-Knorrenschild J; Bolling C; Hofheinz RD; Zhan T; Angermeier S; Ettrich TJ; Siebenhuener AR; Elshafei M; Bechstein WO; Gaiser T; Loose M; Sookthai D; Kopp C; Pauligk C; Al-Batran SE;
J Clin Oncol; 2024 Feb; 42(4):410-420. PubMed ID: 37963317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
